- Home
- OCUL vs AUPH Comparison
OCUL vs AUPH Comparison
Compare OCUL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- AUPH
- Stock Information
- Founded
- OCUL 2006
- AUPH 1993
- Country
- OCUL United States
- AUPH Canada
- Employees
- OCUL N/A
- AUPH N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- OCUL Health Care
- AUPH Health Care
- Exchange
- OCUL Nasdaq
- AUPH Nasdaq
- Market Cap
- OCUL 957.3M
- AUPH 999.8M
- IPO Year
- OCUL 2014
- AUPH 1999
- Fundamental
- Price
- OCUL $7.31
- AUPH $7.75
- Analyst Decision
- OCUL Strong Buy
- AUPH Strong Buy
- Analyst Count
- OCUL 10
- AUPH 2
- Target Price
- OCUL $16.22
- AUPH $11.50
- AVG Volume (30 Days)
- OCUL 1.9M
- AUPH 1.3M
- Earning Date
- OCUL 05-06-2025
- AUPH 05-01-2025
- Dividend Yield
- OCUL N/A
- AUPH N/A
- EPS Growth
- OCUL N/A
- AUPH N/A
- EPS
- OCUL N/A
- AUPH 0.04
- Revenue
- OCUL $63,723,000.00
- AUPH $235,133,000.00
- Revenue This Year
- OCUL $13.32
- AUPH $11.86
- Revenue Next Year
- OCUL $13.13
- AUPH $24.96
- P/E Ratio
- OCUL N/A
- AUPH $193.75
- Revenue Growth
- OCUL 9.03
- AUPH 33.97
- 52 Week Low
- OCUL $4.06
- AUPH $4.71
- 52 Week High
- OCUL $11.78
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- OCUL 51.39
- AUPH 46.63
- Support Level
- OCUL $6.94
- AUPH $7.59
- Resistance Level
- OCUL $7.83
- AUPH $7.83
- Average True Range (ATR)
- OCUL 0.72
- AUPH 0.35
- MACD
- OCUL 0.07
- AUPH -0.02
- Stochastic Oscillator
- OCUL 74.57
- AUPH 65.84
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.